

NCTN Skin Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



Cross-disease trials:



NCTN Skin Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with
A091903	II	Resected Mucosal Melanoma
		Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus
EA6141	11/111	Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
		Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment Versus
NRG-HN014	Ш	Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
		Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II
İ		Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO
S2101	II	Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid
EAY191-E5	II	Tumors: A ComboMATCH Treatment Trial
		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a
		CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH
EAY191-N5	II	Treatment Trial